CONFIDENTIAL1 Zyxell, Inc. Expanding cell therapy Activity Peak of in vitro Expanded Immunocytes By, Yongxin Zhang, Ying Wang, Zhenying Wang and Monica.

Slides:



Advertisements
Similar presentations
How to evaluate the immune response and identify immunedeficit… Dr M.L. Romiti.
Advertisements

Optimization of T cell expansion in a perfusion bioreactor
Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’ May 22, 2012 Joseph Argus, Pardeep Singh, Uland Lau.
1 Steven A. Feldman, Ph.D. Surgery Branch, NCI MEASUREMENT CHALLENGES FOR CAR-T BIOMANUFACTURING January 29, 2016 Adoptive Cell Therapy for the Treatment.
Summary and Conclusion Hypothesis and Rationale
Volume 94, Issue 2, Pages (March 2014)
Life and Death of CD8 T Cells: A Role of IL-12
Volume 66, Issue 6, Pages (June 2013)
Fig. 3. Activation and Th1 differentiation of the P25 TCR-Tg CD4+ T cells after BCG lung infection. The N-P25 TCR-Tg mice were i.t.
Cheng-Ming Sun, Edith Deriaud, Claude Leclerc, Richard Lo-Man  Immunity 
Neoplastic blood cells become pluripotent
Molecular Therapy - Methods & Clinical Development
Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators by Rikke Bæk Sørensen, Sine Reker Hadrup, Inge Marie Svane, Mads Christian.
Elevated telomerase activity and minimal telomere loss in cord blood long-term cultures with extensive stem cell replication by Loretta Gammaitoni, Katja.
Megakaryocyte Growth and Development Factor-Induced Proliferation and Differentiation Are Regulated by the Mitogen-Activated Protein Kinase Pathway in.
Ping Zhang, Jieying Wu, Divino Deoliveira, Nelson J. Chao, Benny J
Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells by Christian P. Kalberer, Uwe Siegler, and Aleksandra Wodnar-Filipowicz.
by Silke Huber, Reinhard Hoffmann, Femke Muskens, and David Voehringer
Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging by Matthias Edinger, Yu-An Cao, Michael R. Verneris,
by Norman Nausch, Ioanna E
Volume 8, Issue 2, Pages (February 1998)
Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists by Christopher T.
Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients by Devi.
by Éric Aubin, Réal Lemieux, and Renée Bazin
Corticosteroids But Not Pimecrolimus Affect Viability, Maturation and Immune Function of Murine Epidermal Langerhans Cells  Wolfram Hoetzenecker, Josef.
Human Progenitor Cells Rapidly Mobilized by AMD3100 Repopulate NOD/SCID Mice with Increased Frequency in Comparison to Cells from the Same Donor Mobilized.
Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell–depleted stem cell transplantation.
Volume 130, Issue 2, Pages (February 2006)
Volume 133, Issue 4, Pages (October 2007)
Human CD4+CD25+ Cells in Combination with CD34+ Cells and Thymoglobulin to Prevent Anti-hematopoietic Stem Cell T Cell Alloreactivity  Dolores Mahmud,
Juan Liu, Erin Harberts, Antonella Tammaro, Nicholas Girardi, Renata B
by Cunren Liu, Shaohua Yu, John Kappes, Jianhua Wang, William E
Cytomegalovirus-Specific Cytotoxic T Lymphocytes Can Be Efficiently Expanded from Granulocyte Colony-Stimulating Factor–Mobilized Hemopoietic Progenitor.
Volume 25, Issue 3, Pages (March 2017)
Cotransplantation of Ex Vivo Expanded and Unexpanded Cord Blood Units in Immunodeficient Mice Using Insulin Growth Factor Binding Protein-2–Augmented.
Cytotoxic CD8+ T Cells Stimulate Hematopoietic Progenitors by Promoting Cytokine Release from Bone Marrow Mesenchymal Stromal Cells  Christian M. Schürch,
Volume 28, Issue 4, Pages (October 2015)
Volume 10, Issue 5, Pages (November 2004)
Volume 23, Issue 10, Pages (October 2015)
Volume 117, Issue 6, Pages (December 1999)
Stanford L Peng, Andrea J Gerth, Ann M Ranger, Laurie H Glimcher 
Volume 22, Issue 3, Pages (March 2005)
Molecular Therapy - Methods & Clinical Development
Volume 43, Issue 2, Pages (August 2015)
Ravindra Majeti, Christopher Y. Park, Irving L. Weissman 
Volume 9, Issue 2, Pages (August 2011)
Volume 33, Issue 4, Pages (October 2010)
Volume 22, Issue 2, Pages (February 2005)
Volume 16, Issue 2, Pages (July 2016)
Volume 23, Issue 1, Pages (January 2015)
Volume 4, Issue 2, Pages (February 2009)
Volume 9, Issue 5, Pages (November 1998)
Opposing Effects of TGF-β and IL-15 Cytokines Control the Number of Short-Lived Effector CD8+ T Cells  Shomyseh Sanjabi, Munir M. Mosaheb, Richard A.
Chie Kudo-Saito, Hiromi Shirako, Tadashi Takeuchi, Yutaka Kawakami 
Volume 31, Issue 4, Pages (October 2009)
Volume 3, Issue 6, Pages (December 2014)
Volume 9, Issue 3, Pages (March 2011)
Lisa P. Daley-Bauer, Grace M. Wynn, Edward S. Mocarski  Immunity 
Volume 34, Issue 3, Pages (March 2011)
Volume 32, Issue 1, Pages (January 2010)
Volume 38, Issue 2, Pages (February 2013)
Moutih Rafei, Elena Birman, Kathy Forner, Jacques Galipeau 
Vaccines for Lung Cancer
Genetic Immunization With In Vivo Dendritic Cell-targeting Liposomal DNA Vaccine Carrier Induces Long-lasting Antitumor Immune Response  Arup Garu, Gopikrishna.
Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation by Wayne R. Godfrey, Mark.
Dissecting the Multifactorial Causes of Immunodominance in Class I–Restricted T Cell Responses to Viruses  Weisan Chen, Luis C. Antón, Jack R. Bennink,
Loss of Transgene following ex vivo Gene Transfer is Associated with a Dominant Th2 Response: Implications for Cutaneous Gene Therapy  Zhenmei Lu, Soosan.
PD-1 inhibition stimulates the proliferation and cytokine secretion of exhausted/senescent CD8+ T cells in vitro. PD-1 inhibition stimulates the proliferation.
Stromal and hematopoietic spleen remodeling in Fas-mutant mice.
Presentation transcript:

CONFIDENTIAL1 Zyxell, Inc. Expanding cell therapy Activity Peak of in vitro Expanded Immunocytes By, Yongxin Zhang, Ying Wang, Zhenying Wang and Monica Zhang

Antigen-specific Immunocyte in vitro Expansion For cancer and chronic virus infection To Reach effective cell number Free from the inhibition to the immunocyte growth, which caused by in vivo cancer cells and infected cells Selective expansion and isolation of antigen- specific immunocytes

Increased CD34+ HSC Expansion in PBSC Culture Using ZYX Bioreactor 10 ml purified CD34+ peripheral blood hematopoietic stem cells (PBSC) were cultured in different conditions. The initial cell density was 0.2x10 6 /ml. ZYX standard Stem cell culture medium II was used in all cultures. P<0.01

10 ml purified CD34+ peripheral blood hematopoietic stem cells (PBSC) were cultured in different conditions. The initial cell density was 0.2x10 6 /ml. ZYX standard Stem cell culture medium II was used in all cultures. Increased CD133+ HSC Expansion in PBSC Culture Using ZYX Bioreactor P<0.01

Increased TNC Expansion in PBSC Culture Using ZYX Bioreactor 10 ml purified CD34+ peripheral blood hematopoietic stem cells (PBSC) were cultured in different conditions. The initial cell density was 0.2x10 6 /ml. ZYX standard Stem cell culture medium II was used in all cultures. Expansion of Total Nucleated Cells (TNC) was plotted in this chart. P<0.01

Increased CD34 and CXCR4 Double Positive Cell Expansion in PBSC Culture Using ZYX Bioreactor CXCR4 expression is positively correlated with engraftmnt. 10 ml purified CD34+ peripheral blood hematopoietic stem cellc (PBSC) were cultured in different conditions. The initial cell density was 0.2x10 6 /ml. ZYX standard Stem cell culture medium II was used in all cultures. Expansion of Total Nucleated Cells (TNC) was plotted in this chart. P<0.01

ISHAGE Guidline for CD34+ Cell Enumeration with Flow Cytometry 1.CD45 Dim: not differentiated into mature myeloid cells 2.Low side scatter: cells are round with single nuclei Our Modification: 1.Cell counting beads addition 2. One more color addition for CD38, CD133 or CD90

P<0.01 Increased Cord Mesenchymal Stem Cell Expansion in Culture with ZYX Bioreactor Cord mesenchymal stem cells were cultured in different condition for 10 days cells were seeded in each culture. Cells were collected by the automatic procedure in ZYX Bioreactor, for other culture condition, the standard tripsin cell lifting procedure was used. MSC cell markers were checked before or after expansion

Engraftment Assay with Expanded HSC in NOD/SCID Mice Control ZYX Bioreactor CD45+ cells CD34+ Cells Positive % in nucleated cells

Evaluation of differentiation potency of expanded cord blood HSC (CBHSC) and peripheral blood HSC (PBHSC) using Colony Forming Unit Assay.

Time points (days) Total cells CD34 + cells Engraftment potency Total cells/CD34 + cells Total cells/Engraftment potency Fold increase in total cells, CD34 + cells and total engraftment potency following culture and the ratios of total cells/CD34 + cells and total cells/engraftment potency

Model of Cell Activity in Expanding Cells Cell number Single cell-based cell activity Total cell-based cell activity Time Activity peak of expanded cells Total cell activity=Single cell-based cell activity*Cell number

Regression functions for TNC fold-expansion and ratio of TNC fold- expansion/CD34 + cell fold-expansion (4a) and ratio of TNC fold- expansion/engraftment potency fold-increase (4b).

Do the individual cell-based functions of immunocytes decline when the cells are expanded in vitro similar to HSC? If so, do the activities of the total immunocytes also have a peak point during the cell expansion? B cells (CD19+, CD 20+, CD22+): Immunoglobulin Production T cells (CD3+): Cytokine productions: IL-2, IL-12 and IL-18 Antigen-specific cytotoxic T cells: virus-infected cell and cancer cell lysis or apoptosis. The answer for both questions are Yes by following tests:

Model of Cell Activity in Expanding Cells Cell number Single cell-based cell activity Total cell-based cell activity Time Activity peak of expanded cells Total cell activity=Single cell-based cell activity*Cell number

How to determine the activity peak of the cells in cell expansion? For the productions immunoglobulins and cytokines, only one test, such as ELISA, would be enough for the required information. However, for the antigen specific CTL activity for different antigens from different patients with different culture medium, it is not that easy. Therefore, the development of a simple method to monitor the CTL toxicity to specific cancer cells is very important. Cell density detection is a optimal method for monitoring CTL toxicity Methods Correlation coefficient (R 2 ) P Value Complexicity Cell density detection0.98 < Cytokine detection ELISA0.82 < Facs Intracellular stain0.79 < ELIspots Assay 0.85 < CTL assay1.0 <

How to determine the activity peak of expanded cancer-specific CTL by monitoring the cell density change and real time reporting the results? Prerequisites: 1.A cell density detector 2. A device for the alternation of proper static and kinetic culture Static culture—provide the adequate contact between antigen particles (cancer cells) and effector cells (T cells), and minimize the shear- stress on the cells. Kinetic culture---ensure effector cells can receive adequate metabolic support and provide a condition for cell density detection. 3.Cells can be evenly distributed in the culture container in the static culture following kinetic culture 4.A suitable program can be used to automatically control and adjust the frequency and interval between static and kinetic culture as well as the speed and changes of the speed of the cell culture container moving in kinetic culture Among many Bioreactors, only ZYX Bioreactor can meet these requirements

Comparison of CMV-CTL number and cytotoxicity between the ZYX btr and the static culture CMV pp65-specific Fold increase (6 th day) Activities (lysis%) at different E:T ratios CD8+ CTL expansion 4:1 8:1 16:1 ZYX btr (n=6, Means±SD)4.76± ± ± ±3.84 Static culture (n=6, Means±SD)3.12± ± ± ±3.77

Inoculated cancer cell number(x10 6 ) Splenocytes from cancer cell line- primed BALB/c mice Cancer cell stimulation and CD8+ selection and expanded in ZYX Btr or Static CTL activity tested in vitro or in vivo (BALB/c mice) P<0.01 P<

Inoculated cancer cell number(x10 6 ) Comparison of Total Human Cancer-specific CTL Expansion between ZYX Bioreactor and Static Culture Blood mononuclear cells from patient with lung cancer Cancer cell stimulation and CD8+ selection and expanded in ZYX Btr or Static CTL activity tested in vitro or in vivo (NOD/SCID mice) P<0.01

Conclusion 1.When the activity of individual cell-based antigen-specific immunocytes declines in the cell expansion, the total cell activity increases at early expansion stage until it reaches a peak. 2. The activity of antigen-specific immunocytes correlates the changes of cell density, cytokine production and many other factors, but the cell density detection would be the be the best option for monitoring the CTL activity. 3. ZYX Bioreactor can determine the optimal cell harvest time by monitor the change of cell density for the highest antigen-specific CTL cytotoxicity.

Acknowledgement

Why not Car-T??? 1.Car-T is a GMO (Genetically Modified Organism,Letenvirus ) E-asCTL is Non-GMO 2.Car-T procedure is very complicated E-asCTL is much simpler 3.Car-T procedure is time consuming, takes several months E-asCTL takes a couple of weeks 4.Car-T procedure is very expansive E-asCTL is much less expansive Now we need to know which one is more effective?